Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yidu TechFRA:0EL -0.40%72 10-Year ROIIC % is -111.83 as of Mar. 2026. GuruFocus rates FRA:0EL with a GF Score™ of 72/100 and a GF Value™ of €0.67 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 484 Healthcare Providers & Services companies, Yidu Tech ranks worse than 94.01% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Yidu Tech does not have enough data to calculate 10-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Yidu Tech 10-Year ROIIC % Related Terms
Yidu Tech 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Yidu Tech's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0EL vs VEEV, BTSG, HQY: 10-Year ROIIC % Comparison
For the Health Information Services subindustry, Yidu Tech's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yidu Tech 10-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yidu Tech's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Yidu Tech's 10-Year ROIIC % falls into.
Yidu Tech's 10-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -7.5207268 (Mar. 2026) - (Mar. 2016) )
/
( 233.071 (Mar. 2026) - (Mar. 2016) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Yidu Tech (FRA:0EL) has a 10-Year ROIIC % of -111.83 as of Mar. 2026. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Yidu Tech and its competitors. According to the industry distribution chart, Yidu Tech ranks #455 out of 484 companies in the Healthcare Providers & Services industry, placing it in the top 94%.
Is Yidu Tech's 10-Year ROIIC % too high?
Yidu Tech's current 10-Year ROIIC % is -111.83. Based on the distribution chart, Yidu Tech ranks #455 out of 484 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Yidu Tech has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Yidu Tech's 10-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Yidu Tech ranks #455 out of 484 companies for 10-Year ROIIC %. This places Yidu Tech in the lower half of its industry. The industry median 10-Year ROIIC % is 3.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Healthcare Providers & Services company?
The median 10-Year ROIIC % among Healthcare Providers & Services companies is 3.40, based on 484 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Yidu Tech and its competitors. For the Healthcare Providers & Services industry, the median 10-Year ROIIC % is 3.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yidu Tech's current 10-Year ROIIC % is -111.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yidu Tech stock overvalued right now?
Based on GuruFocus' analysis, Yidu Tech (FRA:0EL) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.67, compared to a current price of €0.50 — trading 25.7% below its estimated fair value. The current 10-Year ROIIC % is -111.83. Yidu Tech's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Yidu Tech (FRA:0EL), the current 10-Year ROIIC % is -111.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yidu Tech (FRA:0EL) Overvalued in 2026?
Based on GuruFocus' analysis, Yidu Tech stock appears to be undervalued.
The current stock price of €0.50 is trading 25.7% below its estimated GF Value™ of €0.67.
GuruFocus considers Yidu Tech to be Modestly Undervalued.
Key valuation signals for FRA:0EL:
10-Year ROIIC %: -111.83
GF Value™: €0.67 vs. price of €0.50 (25.7% below fair value)
No single metric tells the full story. See the FRA:0EL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yidu Tech Inc offers healthcare solutions built on big data and artificial intelligence (AI) technologies. The company serves various healthcare industry participants, including hospitals, pharmaceutical, biotech, research institutions, insurance companies, etc. Its operating segments are: Big data platform and solutions, Life sciences solutions, and Health management platform and solutions. The majority of the company's revenue is generated from its Big data platform and solutions segment, which provides data intelligence platforms and data analytics-driven solutions (such as Eywa 5.0, Lingxi Intelligent Management, AI Middleware, etc.) for hospitals, healthcare institutions, regulators, and policymakers. Geographically, the company generates maximum revenue from Mainland China.
72GF Score
Get the complete analysis for FRA:0EL
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0EL has been successfully added to your 
